logo
Indian contract drug makers timed their IPOs right. But is the business worth the premium?

Indian contract drug makers timed their IPOs right. But is the business worth the premium?

Mint5 days ago
An anticipated shift in the global pharmaceutical supply chain away from China has investors excited about Indian contract research, development and manufacturing organisations (CRDMOs), companies that offer services from early-stage drug discovery to late-stage drug development.
Export-focused CRDMOs including Anthem Biosciences, Sai Life Sciences and Divi's Laboratories are trading at expensive valuations, reflecting investor enthusiasm as innovator drug companies look at diversifying and derisking their operations. However, experts cautioned that while CRDMOs are expected to post high growth, their financial performances have yet to reflect it.
Bengaluru-based Anthem Biosciences made a stellar debut on the stock exchanges on 21 July, listing on the National Stock Exchange at a premium of 27 percent over its initial public offering price of ₹ 570. The IPO, with an issue size of ₹ 3,395.79 crore, was subscribed 67.42 times. Anthem's stock traded at a price-to-earnings (PE) ratio of 93.24 on 25 July.
'The good news is that… China is a behemoth. So, we have that much headroom to grow,' Ajay Bhardwaj, managing director and chief executive officer, told Mint earlier.
About 65% of India's imported bulk drugs and advanced drug intermediates worth $3.5 billion in FY25 came from China, according to the commerce ministry. The government wants to strengthen local manufacturing through an upgraded drugs production-linked incentive scheme as it pushes for self-sufficiency in bulk drugs that go into manufacturing medicines.
The Indian CRDMO industry today is worth $3-3.5 billion, making up only 2-3% of the global CRDMO market, which is worth $145 billion. It grew at a compound annual growth rate of 15% from 2019-2024, according to a recent report by BCG and IPSO.
The industry is at a tipping point, with strong fundamentals and massive headroom to grow, fueled by competitive advantage in small molecule capabilities, faster startup time, focus on quality and cost advantages, the report noted.
Unlike CRDMOs, CDMOs (contract development and manufacturing organisations) are typically involved in manufacturing already commercialised drugs.
Sai Life Sciences, which made its market debut in December 2024, traded at ₹ 837 on 25 July, close to its high of about ₹ 851, valuing the company at roughly 102 times trailing earnings and about 8.2 times book value.
Divi's Laboratories and Syngene International also traded at premiums, at a PE ratio of 80.31 and 55.09, respectively. In comparison, generic pharmaceutical giants are valued relatively modestly: Sun Pharmaceutical Industries trades at a PE ratio of 37.37, Dr Reddy's Laboratories at 18.84, and Cipla at 23.53.
Sai Life Sciences shares are up over 18% since listing on the NSE. Divi's Laboratories gained 35.56% from 30 July 2024 to 28 July 2025, Piramal Pharma rose 20.36%, while Syngene International's shares were down 12.72%.
Syngene International, a unit of biopharmaceutical company Biocon, kicked off this fiscal's earnings season last week. It posted an 11% year-on-year rise in revenue from operations to ₹ 875 crore for Q1, a robust start compared to its FY25 performance (4% revenue growth YoY). The management maintained its expectation of revenue growth in the mid‑teens for FY26.
Sai Life Sciences delivered 16% revenue growth to ₹ 1,695 crore in FY25. Divi's reported a 19% year-on-year rise in full-year revenue to ₹ 9,360 crore in FY25, while net profit surged 37% to ₹ 2,191 crore.
Divi's is expected to post revenue growth of 18% year-on-year in Q1FY26, according to brokerage BNP Paribas.
'The Indian CDMO sub-sector presents a highly promising opportunity as investors view it as a direct beneficiary of the China+1 thematic,' Sunil Khaitan, managing director leading financing in India at Goldman Sachs, told Mint. 'We expect the capital markets activity in this space to further accelerate over the next 6-12 months.'
The China-plus one theme – to diversify supply chains and reduce overdependence on China – is a key driver, but it's not just that.
CRDMOs are on an aggressive capacity expansion track as they anticipate winning over more clients in the future and bank on technological niches to cater to biotech companies as demand for new technologies and drugs grows.
Anthem has expertise in new chemical entities as well as biologics (drugs made from living organisms or their components) and capabilities to work on RNAi (a gene regulatory mechanism), antibody drug conjugates that target and kill cancer cells, peptides (short chains of amino acids), lipids, and oligonucleotides (synthesised nucleic acids).
OneSource Specialty Pharma, a subsidiary of Strides Pharma, which listed in January, expects its focus on niche areas such as biologics, drug substances, injectables, and drug-device combinations to drive growth. Its offerings in drug-device combinations, particularly for GLP-1s (hormones that regulate blood sugar levels), which are often sold in pen-filled devices, is expected to be a major growth opportunity.
'We are currently executing a 5x expansion of our cartridge-filling capabilities to meet our customer demand and which will significantly boost future revenue,' CEO Neeraj Sharma told Mint in an emailed response.
Anthem Biosciences and Sai Life Sciences did not respond to Mint's queries.
Investors are looking at CRDMOs not just for potential growth driven by these tailwinds but also as diversification of their portfolios, experts said. Opportunities in traditional pharma companies with a focus on domestic formulations and US generics are drying up because of a slowdown in new approvals and regulatory issues.
'The investor would like to have exposure to companies and segments which have the potential for high growth and themes of shifting manufacturing from China to India,' Tausif Shaikh, healthcare and pharma analyst at BNP Paribas, told Mint.
While CRDMOs have reported steady, mid-teen revenue growth, their performance has not been encouraging enough even as valuations remain expensive, Shaikh pointed out.
Unlike sectors such as healthcare services, where one can gauge a company's performance based on metrics like hospital bed occupancy and average revenue per bed, for contract drug manufacturers, management commentary is the main indicator of the company's expected growth and performance, said Shaikh.
Most companies report an uptick in interest from innovators to hire their services and have embarked on aggressive capacity expansion. Syngene plans to boost its biologics manufacturing footprint in FY26 through its newly acquired US facility for $36.5 million.
Divi's Laboratories is undertaking a ₹ 650-700 crore capacity expansion at its existing facilities, while Sai Life Sciences has completed the second phase of its Bidar Unit IV capacity expansion for small-molecule active pharmaceutical ingredients and intermediates.
On the back of this, the growth outlook remains strong.
"Earnings are expected to be strong for export-oriented CDMOs for the next 2-3 years considering the capex projects and potential addition of new molecules,' Shrikant Akolkar, pharma equity research analyst at brokerage Nuvama, told Mint.
However, the CDMO business is non-linear, Akolkar said, adding that one must pay attention to the annual performance and not a couple of quarters of number misses.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'He has his own reasons': Shashi Tharoor on Rahul Gandhi backing Trump's ‘dead economy' remark
'He has his own reasons': Shashi Tharoor on Rahul Gandhi backing Trump's ‘dead economy' remark

Hindustan Times

time20 minutes ago

  • Hindustan Times

'He has his own reasons': Shashi Tharoor on Rahul Gandhi backing Trump's ‘dead economy' remark

Congress MP Shashi Tharoor on Saturday said he would not comment on Rahul Gandhi's remarks about US President Donald Trump's 'dead economy' comment, but said India's trade ties with America are important and should not be affected. Congress MP Shashi Tharoor during the Monsoon session of Parliament, in New Delhi.(PTI File) Tharoor, who represents Thiruvananthapuram in the Lok Sabha, said, 'I don't want to comment on what my party leader has said. He has his own reasons for saying it. My concern is much more that our relationship with the US, as a strategic and economic partnership, is important for us.' The Congress leader said India must protect its strong trade ties with the US, emphasising that America is one of the country's biggest export markets, with around $90 billion worth of goods going there annually. 'We are exporting something like 90 billion worth of goods to America. We can't therefore be in a position where we are going to lose that or have it diminish significantly. Some people say Oh, that is only 2 per cent of our GDP, but in terms of percentage of our exports, America is one of our largest markets,' he claimed. On the issue of tariffs, Shashi Tharoor backed India's trade negotiators, saying, 'When we look at the tariff question, we must wish our negotiators strength and courage in working out a fair deal for India.' 'We should also be talking to other regions for exporting our goods. Then we could make up for some of what we might lose in the US. We have to support our negotiators,' Tharoor added. Donald Trump recently stirred controversy by calling India's economy 'dead' while announcing new 25 per cent tariffs on Indian goods. In a post on Truth Social, Trump said, 'India and Russia can take their dead economies down together, for all I care.' The remarks were seen as a sharp escalation in trade tensions and drew mixed responses from Indian politicians. Congress leader and Lok Sabha MP Rahul Gandhi appeared to agree with Trump's view, saying India's economy was indeed in poor shape. 'I don't care what Trump said. The reality is that India's economy is dead. And it has been murdered by the BJP government,' he told reporters.

Employee joins Indian startup after decades of working with US firms, almost dies: ‘Damaged heart, uncertain future'
Employee joins Indian startup after decades of working with US firms, almost dies: ‘Damaged heart, uncertain future'

Time of India

time34 minutes ago

  • Time of India

Employee joins Indian startup after decades of working with US firms, almost dies: ‘Damaged heart, uncertain future'

A professional recently shared a harrowing experience on the " Indian Workplace " subreddit, shedding light on the deeply damaging effects of a toxic job environment. After spending nearly twenty years with multinational companies across the US and Europe, he had grown accustomed to work cultures that valued transparency, boundaries, and employee well-being. However, after being laid off unexpectedly, he found himself forced to accept an opportunity at an Indian startup—despite early signs that it was far from healthy. Warning Signs Ignored From the second week of joining, the red flags were unmistakable. Revenue figures were being manipulated, the leadership team operated with unchecked egos, and employees were expected to be available nearly around the clock—from late morning to the early hours of the next day. As days turned into weeks, he became immersed in a cycle of gaslighting, favoritism, and impossible client demands, all while facing zero regard for boundaries or dignity. Explore courses from Top Institutes in Please select course: Select a Course Category Artificial Intelligence Cybersecurity MBA Data Science Design Thinking others Operations Management Digital Marketing PGDM Healthcare Project Management Technology Data Science Others Finance Public Policy Leadership CXO healthcare Product Management Data Analytics MCA Degree Management Skills you'll gain: Duration: 7 Months S P Jain Institute of Management and Research CERT-SPJIMR Exec Cert Prog in AI for Biz India Starts on undefined Get Details Despite knowing he should walk away, the fear of joblessness during a volatile hiring climate kept him chained to the role. The daily stress began to erode not just his emotional health but also his sense of identity and ethical compass. Depression quietly set in, while the pressure and psychological abuse from leadership intensified. Breaking Point and Aftermath Eventually, he could no longer withstand the atmosphere and chose to resign—even though he had no other job secured. But the toll had already been taken. Just weeks after quitting, he suffered a massive heart attack. Two emergency stents were inserted to save his life, and doctors warned that a delay of just half an hour could have been fatal. Now back home, unemployed and recovering with a weakened heart, he reflects on whether the monthly pay he earned was worth the irreversible damage. His answer: absolutely not. He admitted that while he once believed he had no alternative, lying in a hospital bed brought clarity. There's always a choice—we just often fail to recognize it until the consequences become physical. "Now I'm home—jobless, with a damaged heart and an uncertain future. Was that monthly salary worth permanently destroying my health? Hell no..." he wrote. A Caution to Others He urged others working in similarly suffocating environments not to sacrifice their well-being for financial comfort. No paycheck is worth permanent health damage. Survival should never come at the cost of one's physical or mental integrity. While he learned this truth the hard way, he hoped others would heed the warning sooner. Voices of Empathy and Shared Pain The post struck a chord with Reddit users. Many responded with compassion, echoing similar experiences. One commenter shared how her husband—only 31 years old—suffered two heart attacks and needed three stents due to intense stress in the hotel industry. She had to leave her own job to care for him. Others reminded the original poster that while joblessness is daunting, it is still a better fate than losing one's life. Encouragement flowed in—praising him for choosing himself over a paycheck and wishing him strength for the road ahead. Some even advised moving to quieter towns for peace and healthier lifestyles. For many, this story served as a powerful reminder: work can wait, but health cannot.

'He Has His Own Reasons': Shashi Tharoor On Rahul Gandhi Backing Trump's 'Dead Economy' Jibe
'He Has His Own Reasons': Shashi Tharoor On Rahul Gandhi Backing Trump's 'Dead Economy' Jibe

News18

time44 minutes ago

  • News18

'He Has His Own Reasons': Shashi Tharoor On Rahul Gandhi Backing Trump's 'Dead Economy' Jibe

Last Updated: Shashi Tharoor declined to comment on Rahul Gandhi backing Donald Trump's "dead economy" jibe towards India, a stance that was criticised by several BJP leaders. Congress leader Shashi Tharoor declined to comment on his party colleague Rahul Gandhi's endorsement of US President Donald Trump's 'dead economy" jibe towards India amid trade talks, saying the priority was on a fair deal for New Delhi. Speaking to reporters on Saturday, Tharoor said, 'I don't want to comment on what my party leader has said. He has his reasons for saying so. My concern is that our relationship with the US, as a strategic and economic partnership, is important for us." 'We are exporting around $90 billion worth of goods to America. We can't be in a position to lose that or have it diminish significantly," he said. 'We must wish our negotiators strength to get a fair deal for India." #WATCH | Mumbai | On Lok Sabha LoP and Congress MP Rahul Gandhi agreeing with US President Donald Trump's 'dead economy' remark, Congress MP Shashi Tharoor says, 'I don't want to comment on what my party leader has said. He has his reasons for saying so. My concern is that our… — ANI (@ANI) August 2, 2025 Tharoor also said India should be talking to other regions for exporting Indian goods to make up for some of what it may lose to the United States. 'We already have an FTA with the UK, which has tremendous potential. We are well advancing in talks with the EU. If we have a good agreement with the EU, Japan and other countries, we could make up for some of what we might lose in the US, but we cannot lose everything," he added. 'Dead Economy' Tharoor's remarks came after Donald Trump imposed 25% tariffs on Indian goods, along with an unspecified penalty, citing its refusal to open up agricultural markets and oil imports from Russia, which Washington says is fuelling the Ukraine conflict. In a harsh statement, Trump later said, 'I don't care what India does with Russia. They can take their dead economies down together, for all I care." Rahul Gandhi agreed with Trump's statement, saying, 'Everybody knows that the Indian economy is a dead economy. I am glad that President Trump has stated a fact. The entire world knows that the Indian economy is a dead economy. BJP has finished the economy to help Adani." His statements drew a fierce response from the BJP, with top leaders accusing him of speaking against the nation. However, Tharoor disagreed with Trump's views and said, 'No, not at all. That is not the case, and we all know it." Several Congress and Opposition leaders also did not back Rahul Gandhi's endorsement of Trump's views and said that the 'Indian economy is not dead". view comments First Published: August 02, 2025, 17:52 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store